相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。IDH mutation impairs histone demethylation and results in a block to cell differentiation
Chao Lu et al.
NATURE (2012)
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Sevin Turcan et al.
NATURE (2012)
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Wei Xu et al.
CANCER CELL (2011)
Primer extension based quantitative polymerase chain reaction reveals consistent differences in the methylation status of the MGMT promoter in diffusely infiltrating gliomas (WHO grade II-IV) of adults
Erik Vassella et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors
Marta Mellai et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Molecular Classification of Low-Grade Diffuse Gliomas
Young Ho Kim et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Houtan Noushmehr et al.
CANCER CELL (2010)
A Pyrosequencing-Based Assay for the Rapid Detection of IDH1 Mutations in Clinical Samples
Prashanth Setty et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2010)
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
C. Houillier et al.
NEUROLOGY (2010)
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
Christian Hartmann et al.
ACTA NEUROPATHOLOGICA (2009)
IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas
Takuya Watanabe et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
miR-15a and miR-16 Are Implicated in Cell Cycle Regulation in a Rb-Dependent Manner and Are Frequently Deleted or Down-regulated in Non-Small Cell Lung Cancer
Nora Bandi et al.
CANCER RESEARCH (2009)
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Marc Sanson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide
H. J. Dubbink et al.
NEUROLOGY (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Oligodendrogliomas: Molecular Biology and Treatment
Jacolien E. C. Bromberg et al.
ONCOLOGIST (2009)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
Loss of NOTCH2 Positively Predicts Survival in Subgroups of Human Glial Brain Tumors
Jean-Louis Boulay et al.
PLOS ONE (2007)
Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy
Luigi Mariani et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas
H Ohgaki et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Survival model predictive accuracy and ROC curves
PJ Heagerty et al.
BIOMETRICS (2005)
Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas
Y Okamoto et al.
ACTA NEUROPATHOLOGICA (2004)
The impact of tumour volume and surgery on the outcome of adults with supratentorial WHO grade II astrocytomas and oligoastrocytomas
L Mariani et al.
ACTA NEUROCHIRURGICA (2004)
Prognostic factors for survival in adult patients with cerebral low-grade glioma
F Pignatti et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
M Esteller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
